InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2025-03-24 | George Whitesides(D-CA27) | house | Sale | $15,001 - $50,000 |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Total revenues | $32.5M+14946.3% | $216K | — | — |
| Research and development | $37.4M-0.6% | $37.6M-7.3% | $40.6M-99.9% | $63.39B |
| Selling, general and administrative | $73.7M+6.5% | $69.2M-1.3% | $70.1M-99.9% | $67.07B |
| Impairment of long-lived assets (non-cash) | $0-100.0% | $4.5M | — | — |
| Total expenses | $111.1M-0.2% | $111.3M-1.9% | $113.5M-99.9% | $143.30B |
| Loss from operations | -$3.6M+92.3% | -$46.9M+16.2% | -$56.0M+99.9% | -$91.96B |
| Net gain on realized contingent milestone and royalty assets | $75.1M | — | — | — |
| TRELEGY milestone income | $50.0M | — | — | — |
| Interest expense (non-cash) | -$2.5M+3.3% | -$2.5M-8.3% | -$2.4M | — |
| Interest and other income, net | $10.2M+108.4% | $4.9M-46.5% | $9.1M | — |
| Income (loss) before income taxes | $129.2M+389.7% | -$44.6M | — | — |
| Provision for income tax benefit (expense) | -$23.4M-97.8% | -$11.8M | — | — |
| Net income (loss) | $105.9M+287.7% | -$56.4M | — | — |
| Net income (loss) per share - basic (in dollars per share) | $2K+282.6% | -$1K | — | — |
| Net income (loss) per share - diluted (in dollars per share) | $2K+279.1% | -$1K | — | — |
| Shares used to compute net income (loss) per share - basic (in shares) | $50.3M+3.0% | $48.8M | — | — |
| Shares used to compute net income (loss) per share - diluted (in shares) | $51.5M+5.4% | $48.8M | — | — |
| Collaboration Agreement | ||||
| Total revenues | $32.5M+14946.3% | $216K | — | — |
| Licensing and Milestone | ||||
| Total revenues | $32.5M+14946.3% | $216K | — | — |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Summers Value Fund adds TBPH, exits ADMA among Q1 moves
Laughing Water Capital’s New Position: Theravance Biopharma (TBPH)
Theravance Biopharma: A Special Situation With A 50-100% Likely Upside
B. Riley Lifts PT on Theravance Biopharma (TBPH) to $17 From $14